Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea

NCT06550882 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06550882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06550882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance (Use-result Surveillance) of OBIZUR Injection [Susoctocog Alpha (Porcine Antihemophilic Factor VIII, Recombinant)] for the Approved Indications in South Korea
Lead sponsor
Takeda
Phase
Observational
Overall status
Recruiting
Start date
July 22, 2025
Completion date
December 31, 2026
Enrollment
9 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acquired hemophilia a